{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:50:04Z","timestamp":1785178204179,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.modpat.2024.100654","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T18:32:15Z","timestamp":1731090735000},"page":"100654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evidence for Unified Assessment Criteria of HER2 Immunohistochemistry in Colorectal Carcinoma"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-9843","authenticated-orcid":false,"given":"Mark G.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harris B.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda K.","family":"Yantiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Garcia-Buitrago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinru","family":"Shia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Radovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Oberley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-0985","authenticated-orcid":false,"given":"Jaclyn F.","family":"Hechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.modpat.2024.100654_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"issue":"9742","key":"10.1016\/j.modpat.2024.100654_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"7407","key":"10.1016\/j.modpat.2024.100654_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.modpat.2024.100654_bib4","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2024.100654_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3892\/etm.2014.2063","article-title":"Significance of human epidermal growth factor receptor 2 expression in colorectal cancer","volume":"9","author":"Tu","year":"2015","journal-title":"Exp Ther Med"},{"issue":"6","key":"10.1016\/j.modpat.2024.100654_bib6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2024.100654_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"issue":"15 suppl","key":"10.1016\/j.modpat.2024.100654_bib8","article-title":"Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: the HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)","volume":"31","author":"Marsoni","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100654_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100654_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100654_bib11","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2024.100654_bib12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.modpat.2024.100654_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.modpat.2024.100654_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ajcp\/aqz031","article-title":"Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma","volume":"152","author":"Cenaj","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.modpat.2024.100654_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.02.004","article-title":"Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer","volume":"66","author":"Shimada","year":"2017","journal-title":"Hum Pathol"},{"issue":"16","key":"10.1016\/j.modpat.2024.100654_bib16","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1200\/JCO.23.01507","article-title":"HER2 gene expression levels are predictive and prognostic in patients with metastatic colorectal cancer enrolled in CALGB\/SWOG 80405","volume":"42","author":"Battaglin","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.modpat.2024.100654_bib17","article-title":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors","year":"2024","journal-title":"FDA"},{"issue":"4","key":"10.1016\/j.modpat.2024.100654_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/modpathol.3800555","article-title":"Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm","volume":"19","author":"Hanna","year":"2006","journal-title":"Mod Pathol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:34:10Z","timestamp":1769916850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395224002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0893395224002345"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100654","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for Unified Assessment Criteria of HER2 Immunohistochemistry in Colorectal Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100654"}}